A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis.
Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic.
Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
Medical device maker Abbott has secured a series of case-ending sanctions against a wholesaler, bringing the five-year-long dispute to a close.
Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
The Costa Rican government has asked the World Health Organization to create a voluntary pool to collect patent rights for technologies that are useful for the detection, prevention, control and treatment of the COVID-19 pandemic.
Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office.